Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Immunocore Holdings Plc ADR
(NQ:
IMCR
)
58.46
+0.46 (+0.79%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
403,551
Open
57.75
Bid (Size)
23.18 (2)
Ask (Size)
92.70 (2)
Prev. Close
58.00
Today's Range
56.10 - 58.94
52wk Range
42.21 - 76.98
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Immunocore announces upcoming presentation and posters at ASCO 2024
April 24, 2024
From
Immunocore Holdings plc
Via
GlobeNewswire
Immunocore Hldgs Stock: A Deep Dive Into Analyst Perspectives (8 Ratings)
April 11, 2024
Via
Benzinga
Performance
YTD
-18.40%
-18.40%
1 Month
-8.05%
-8.05%
3 Month
-16.46%
-16.46%
6 Month
+36.43%
+36.43%
1 Year
-0.56%
-0.56%
More News
Read More
Immunocore to present at upcoming investor conferences
April 04, 2024
From
Immunocore Holdings Limited
Via
GlobeNewswire
Billionaire’s Biotech Bets: 3 Stocks Dominating Bill Gates’ Portfolio
March 13, 2024
Via
InvestorPlace
Immunocore presented two posters at CROI 2024
March 05, 2024
From
Immunocore Holdings Limited
Via
GlobeNewswire
Key Takeaways From Immunocore Hldgs Analyst Ratings
February 29, 2024
Via
Benzinga
Immunocore Hldgs's Earnings: A Preview
February 27, 2024
Via
Benzinga
Immunocore's Pipeline Is Among The Strongest In Broader Biotech Universe: Analyst
January 05, 2024
Via
Benzinga
Immunocore to present at upcoming investor conferences
March 01, 2024
From
Immunocore Holdings Limited
Via
GlobeNewswire
Immunocore reports fourth quarter and full year 2023 financial results and provides a business update
February 28, 2024
From
Immunocore Holdings Limited
Via
GlobeNewswire
Immunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) in combination with nivolumab in its registrational Phase 3 first-line advanced cutaneous melanoma trial
February 22, 2024
From
Immunocore Holdings Limited
Via
GlobeNewswire
Immunocore to report fourth quarter and full year 2023 financial results and host call on February 28, 2024
February 21, 2024
From
Immunocore Holdings Limited
Via
GlobeNewswire
5 Analysts Have This to Say About Immunocore Hldgs
November 20, 2023
Via
Benzinga
Analyst Ratings for Immunocore Hldgs
November 02, 2023
Via
Benzinga
Immunocore Prices Upsized Convertible Senior Notes Offering
January 30, 2024
From
Immunocore Holdings Limited
Via
GlobeNewswire
Immunocore Announces Proposed Convertible Senior Notes Offering
January 29, 2024
From
Immunocore Holdings Limited
Via
GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
January 16, 2024
Via
Benzinga
Why Applied Therapeutics Shares Are Trading Lower By Over 35%? Here Are Other Stocks Moving In Friday's Mid-Day Session
January 05, 2024
Via
Benzinga
Immunocore announces strategic priorities and pipeline expansion ahead of 42nd Annual J.P. Morgan Healthcare Conference presentation
January 05, 2024
From
Immunocore Holdings Limited
Via
GlobeNewswire
Immunocore to present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024
From
Immunocore Holdings Limited
Via
GlobeNewswire
AGC Biologics to Prepare Late Phase and Commercial Runs for Immunocore
November 20, 2023
Via
News Direct
Immunocore Reports Third Quarter 2023 Financial Results and Provides Business Update
November 07, 2023
From
Immunocore Holdings Limited
Via
GlobeNewswire
Immunocore announces upcoming poster presentations at SITC Annual Meeting 2023 and SMR Congress 2023
November 01, 2023
From
Immunocore Holdings Limited
Via
GlobeNewswire
Immunocore to present at upcoming investor conferences
October 30, 2023
From
Immunocore Holdings Limited
Via
GlobeNewswire
Immunocore presents three-year overall survival data from the KIMMTRAK Phase 3 trial
October 21, 2023
From
Immunocore Holdings Limited
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.